| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.73 | 2e-07 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.13 | 2e-05 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.6 | 0.0002 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0002 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.18 | 0.0003 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0003 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0003 |